• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sigma-Aldrich acquires Research Organics

Sigma-Aldrich acquires Research Organics

April 4, 2012
CenterWatch Staff

Sigma-Aldrich, a life science and high technology company, has acquired all outstanding shares of Cleveland-based Research Organics, a supplier of high purity biochemicals.

The acquisition will expand Sigma-Aldrich’s buffer production capacity and increase its portfolio of PharmaGrade raw materials for the biopharmaceutical and diagnostic markets. Research Organics will transition into SAFC, the custom manufacturing and services business unit of Sigma-Aldrich. 

"This acquisition is an outstanding complement to our existing raw materials portfolio and will help us provide more innovative solutions for some of our customers' toughest supply challenges,” said Gilles Cottier, executive vice president of Sigma-Aldrich and president of SAFC. “It will also enable us to provide SAFC's customers with true dual sourcing of buffers from two of the world's leading manufacturing sites." 

Founded in the 1950's, Research Organics was a pioneer in manufacturing zwitterionic biological buffers and developing the HEPES buffer as an industry-standard. 

Rob Sternfeld, president of Research Organics, said, "The acquisition provides the resources to expand the growth of our business, to enhance our product line and to upgrade our facilities to meet ever changing industry requirements.”

Terms of the purchase were not disclosed. Sigma-Aldrich expects the acquisition to be neutral to earnings per share in 2012.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing